Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 13/20 | 0.78 |
| ▸ | RARG | P13631 | 13/20 | 0.78 |
| ▸ | RARA | P10276 | 12/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.75 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 4/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19560666 | 0.89 | RARA (0.82) | RARBRARGRARACYP3A4KMT2A | |
| SCHEMBL17885756 | 0.89 | RARB (0.81) | RARBRARGRARACYP3A4KMT2A | |
| Tazarotene SCHEMBL29512592 | 0.88 | RARA (1.00) | RARBRARGRARACYP3A4KMT2A | |
| Tazarotene SCHEMBL29397163 | 0.88 | RARA (1.00) | RARBRARGRARACYP3A4KMT2A | |
| Tazarotene SCHEMBL3134 | 0.88 | RARA (1.00) | RARBRARGRARACYP3A4KMT2A | |
| Tazarotene SCHEMBL5747908 | 0.88 | RARA (1.00) | RARBRARGRARACYP3A4KMT2A | |
| Tazarotene SCHEMBL6101987 | 0.87 | RARA (0.98) | RARBRARGRARACYP3A4KMT2A | |
| Tazarotenic Acid SCHEMBL678713 | 0.86 | CYP3A4 (1.00) | RARBRARGRARACYP3A4KMT2A | |
| SCHEMBL14330777 | 0.86 | CYP3A4 (0.84) | RARBRARGRARACYP3A4KMT2A | |
| Tazarotenic Acid SCHEMBL29466098 | 0.86 | CYP3A4 (1.00) | RARBRARGRARACYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170326159-A1 | METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID | WISCONSIN ALUMNI RES FOUND (US) | 2017-11-16 | — | — | US | disclosed |
| US-20160235770-A1 | METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2016-08-18 | — | — | US | disclosed |
| US-9339509-B2 | Methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin D analog with or without a retinoid | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-05-17 | — | — | US | disclosed |
| US-20140018332-A1 | METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-8404667-B2 | 2-methylene-19-nor-20(S)-1 alpha -hydroxy-bishomopregnacalciferol; 13-cis-retinoic acid activator; acne, psoriasis, ichthyosis, photoaging, photodamaged skin, skin cancer | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110195941-A1 | Methods of Use To Orally and Topically Treat Acne and Other Skin Conditions By Administering a 19-NOR Containing Vitamin D Analog With or Without a Retinoid | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2011-08-11 | — | — | US | disclosed |
| US-20080261925-A1 | COMPOUNDS, COMPOSITIONS, KITS AND METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261925-A1 | COMPOUNDS, COMPOSITIONS, KITS AND METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID | CYP2R1, CYP24A1, VDR | RARB 8/4885RARG 7/4885RARA 4/4885 |
| US-20170326159-A1 | METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID | CYP24A1, CYP2R1, VDR | RARB 6/4885RARG 7/4885RARA 4/4885 |
| US-20140018332-A1 | METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID | CYP24A1, CYP2R1, VDR | RARB 6/4885RARG 7/4885RARA 4/4885 |
| US-20110195941-A1 | Methods of Use To Orally and Topically Treat Acne and Other Skin Conditions By Administering a 19-NOR Containing Vitamin D Analog With or Without a Retinoid | CYP24A1, CYP2R1, VDR | RARB 6/4885RARG 7/4885RARA 4/4885 |
| US-20160235770-A1 | METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID | CYP24A1, CYP2R1, VDR | RARB 6/4885RARG 7/4885RARA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.